Despite potential benefits, the therapy remains in limited use for myeloproliferative neoplasms (MPNs). Pegylated interferons are a meaningful therapeutic option for the treatment of ...

A combination of standard interferon--2b and ribavirin is currently recommended as the treatment of choice for patients with hepatitis C virus (HCV) infection considered to be at greatest risk of ...

The concept behind pegylated interferon involves the covalent attachment of interferon to an inert polyethylene glycol polymer to produce a large molecule with a much longer half-life. The rationale ...

Over the past 35 years, interferons have been explored in various formulations for the management of Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), such as essential ...

Treatment with the investigational drug bulevirtide plus pegylated interferon alfa-2a (PegIFNα) resulted in more patients achieving undetectable levels of hepatitis D virus (HDV) RNA compared with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A single dose of pegylated interferon lambda used as ...

Chronic infection with HBV or HCV can lead to progressive cirrhosis, liver failure, and an increased risk of hepatocellular carcinoma. Before the availability of pegylated interferons (PEG-IFNs), ...

Availability of a drug regimen that eradicates the hepatitis C virus (HCV) in more than half of treated patients provides the medical community with a powerful new weapon to diminish the anticipated ...

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma PEG-IFN (1, 2, and 3 μg/kg per week) was ...

High-dose interferon (IFN)α-2b has shown benefits in the adjuvant treatment of melanoma, but relapse-free and overall survival remain poor, despite the use of chemotherapy, vaccines, and combinations ...

Washington, D.C. - April 3, 2017 -Hepatitis B is notoriously difficult to eradicate with currently available agents.. Now, in a new study, a novel form of "pegylated" interferon-β has reduced ...